Press release
Desmoid Tumors Pipeline Outlook, Clinical Trials, FDA Approvals, and Companies 2024 (Updated)
Desmoid Tumors Pipeline
In the Desmoid Tumors Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Desmoid Tumors NDA approvals (if any), and product development activities comprising the technology, Desmoid Tumors collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
To explore more information on the latest breakthroughs in the Desmoid Tumors Pipeline treatment landscape of the report, click here @ Desmoid Tumors Pipeline Outlook- https://www.delveinsight.com/report-store/desmoid-tumors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Desmoid Tumors Pipeline Report
• DelveInsight's Desmoid Tumors Pipeline analysis depicts a robust space with 12+ active players working to develop 12+ pipeline treatment therapies.
• The leading companies working in the Desmoid Tumors market include Ayala Pharmaceuticals, Inc., SpringWorks Therapeutics, Recursion Pharmaceuticals Inc., Iterion Therapeutics, 180 Life Sciences, AFT Pharma, Timber Pharmaceuticals, MedPact, Intas Pharmaceutical, Jina pharmaceuticals, and others.
• Promising Desmoid Tumors Pipeline Therapies in the various stages of development include Nirogacestat oral tablet, AL102, Cryoablation, Tegavivint, Imatinib, Sirolimus, Nab-Rapamycin, E7386, and others.
• March 2024:- Recursion Pharmaceuticals- A Phase 1b-2, Multicenter, Trial To Evaluate The Efficacy, Safety, Pharmacokintetics, And Pharmacodynamics Of REC-4881 in Patients With Familial Adenomatous Polyposis (FAP). This is a Phase 1b/2, trial to evaluate efficacy, safety, pharmacokinetics and pharmacodynamics of REC-4881 in participants with Familial Adenomatous Polyposis (FAP). This two-part study will treat participants with phenotypic classical FAP with disease involvement of the duodenum or the residual colon/rectum/pouch as the primary disease site.
• January 2024:- MedPacto Inc.- A Phase II, Open-Label, Randomized, Controlled Study to Evaluate Efficacy and Safety of Vactosertib and Imatinib Combination in Patients With Advanced Desmoid Tumor (Aggressive Fibromatosis) Compared With Imatinib Monotherapy. Vactosertib and imatinib combination in patients with advanced desmoid tumor/aggressive fibromatosis (DT/AF) compared with imatinib monotherapy.
Desmoid Tumors Overview
Desmoid tumors is an abnormal growth that arises from connective tissue. "Desmoid"" comes from the Greek word desmos, which means tendon or band-like. These are also known as aggressive fibromatosis or desmoid-type fibromatosis.
For further information, refer to the detailed Desmoid Tumors Unmet Needs, click here for Desmoid Tumors Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/desmoid-tumors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Desmoid Tumors Emerging Drugs Profile
• Nirogacestat: SpringWorks Therapeutics
• Tegavivint: Iterion Therapeutics
Desmoid Tumors Pipeline Therapeutics Assessment
There are approx. 12+ key companies which are developing the therapies for Desmoid Tumors. The companies which have their Desmoid Tumors drug candidates in the most advanced stage, i.e. phase III include, SpringWorks Therapeutics.
Request a sample and discover the recent advances in Desmoid Tumors Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Desmoid Tumors Segmentation- https://www.delveinsight.com/sample-request/desmoid-tumors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Desmoid Tumors Drugs and Companies
• Nirogacestat Oral Tablet: SpringWorks Therapeutics Inc.
• AL102: Ayala Pharmaceuticals Inc.
• Nirogacestat: Stanford University.
Desmoid Tumors Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Desmoid Tumors Therapeutics Market include-
Ayala Pharmaceuticals, Inc., SpringWorks Therapeutics, Recursion Pharmaceuticals Inc., Iterion Therapeutics, 180 Life Sciences, AFT Pharma, Timber Pharmaceuticals, MedPact, Intas Pharmaceutical, Jina pharmaceuticals, and others.
Dive deep into rich insights for drugs for the Desmoid Tumors Pipeline, Click here @ Desmoid Tumors Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/desmoid-tumors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Desmoid Tumors Pipeline Report
• Coverage- Global
• Companies- Ayala Pharmaceuticals, Inc., SpringWorks Therapeutics, Recursion Pharmaceuticals Inc., Iterion Therapeutics, 180 Life Sciences, AFT Pharma, Timber Pharmaceuticals, MedPact, Intas Pharmaceutical, Jina pharmaceuticals, and others.
• Therapies- Nirogacestat oral tablet, AL102, Cryoablation, Tegavivint, Imatinib, Sirolimus, Nab-Rapamycin, E7386, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Desmoid Tumors Merger and acquisitions, Licensing Activities- https://www.delveinsight.com/sample-request/desmoid-tumors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Desmoid Tumors: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Desmoid Tumors - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Desmoid Tumors Collaboration Deals
9. Late Stage Products (Phase III)
10. Nirogacestat: SpringWorks Therapeutics
11. Mid Stage Products (Phase II)
12. Tegavivint: Iterion Therapeutics
13. Drug profiles in the detailed report…..
14. Early Stage Products (Phase I)
15. Endoxifen: Intas Pharmaceuticals/Jina Pharmaceuticals
16. Drug profiles in the detailed report…..
17. Pre-clinical and Discovery Stage Products
18. Collagenase injection: BioSpecifics Technologies Corp.
19. Drug profiles in the detailed report…..
20. Inactive Products
21. Desmoid Tumors Key Companies
22. Desmoid Tumors Key Products
23. Desmoid Tumors- Unmet Needs
24. Desmoid Tumors- Market Drivers and Barriers
25. Desmoid Tumors- Future Perspectives and Conclusion
26. Desmoid Tumors Analyst Views
27. Desmoid Tumors Key Companies
28. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Desmoid Tumors Pipeline Outlook, Clinical Trials, FDA Approvals, and Companies 2024 (Updated) here
News-ID: 3489494 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Desmoid
Desmoid Tumors Market Future Business Scope Analysis Report, Marketing Strategy, …
Introduction
The Desmoid Tumors Market focuses on a rare, locally aggressive, but non-metastatic type of soft tissue tumor that arises from fibroblasts. Also known as aggressive fibromatosis, desmoid tumors can occur anywhere in the body, but are most common in the abdomen, shoulder, and limbs. Although they do not spread to distant organs, they can cause significant morbidity due to local invasion and recurrence.
Over the past decade, treatment strategies have evolved…
Desmoid Tumors Market Poised for 6.8 % Growth, Set to Hit $4.13 Billion by 2029
How Are the key drivers contributing to the expansion of the desmoid tumors market?
The escalating prevalence of cancer is predicted to catalyze the expansion of the desmoid tumor market. Cancer is characterized by abnormal cellular growth in the body, which can uncontrollably spread and potentially damage nearby tissues and organs. With global cancer rates climbing, there has been a corresponding surge in demand for refined chemotherapeutic agents, having a favorable…
Top Factor Driving Desmoid Tumors Market Growth in 2025: Rising Global Cancer In …
How Big Is the Desmoid Tumors Market Expected to Be, and What Will Its Growth Rate Be?
The desmoid tumors market is set to grow from $2.97 billion in 2024 to $3.18 billion in 2025, at a CAGR of 7.3%. Growth is driven by advancements in medical imaging, genetic research, surgical innovations, and increased awareness and education on these tumors.
The desmoid tumors market is forecast to grow strongly, reaching $4.13 billion…
Top Factor Driving Desmoid Tumors Market Growth in 2025: Rising Global Cancer In …
How Big Is the Desmoid Tumors Market Expected to Be, and What Will Its Growth Rate Be?
The desmoid tumors market is set to grow from $2.97 billion in 2024 to $3.18 billion in 2025, at a CAGR of 7.3%. Growth is driven by advancements in medical imaging, genetic research, surgical innovations, and increased awareness and education on these tumors.
The desmoid tumors market is forecast to grow strongly, reaching $4.13 billion…
Desmoid Tumors Market Strategies 2024-2033: Segments, Analysis, Trends, Opportun …
"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Desmoid Tumors Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $3.84 billion In 2028 At…
Advancements in Desmoid Tumor Treatment Propel Market Growth to $3.84 Billion by …
The desmoid tumors market size has grown strongly in recent years. It will grow from $2.76 billion in 2023 to $2.97 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to advancements in medical imaging, genetic research and understanding, surgical innovations, awareness and education, patient advocacy.
The desmoid tumors market size is expected to see strong growth in the…
